CLNN — Clene Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1822791 ·
Last close
$3.22
Market Cap
$46.37M
52W High
$10.84
52W Low
$3.02
ADV30
96,432
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 56,000 | 40,000 | -6,105,000 | 3,915,000 | 22,157,000 | 9,887,000 | 36,965,000 |
| Jun 2026 | 90,000 | 54,000 | -5,164,000 | -13,424,000 | 23,041,000 | 9,671,000 | 47,818,000 |
| Mar 2026 | 15,000 | 15,000 | -1,692,000 | -8,091,000 | 21,665,000 | 5,939,000 | 40,471,000 |
| Dec 2025 | 77,000 | 54,000 | -7,244,000 | -9,226,000 | 18,131,000 | 5,189,000 | 35,723,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,532,000
Investing CF
$-90,000
Financing CF
$18,498,000
CapEx
$-79,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.57
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-325,896,000
Inventory
$41,000
Receivables
$1,408,000
ST Investments
—
EBIT TTM
$-23,929,000
Pretax Income TTM
$-26,826,000
Interest Exp TTM
$2,897,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$197,000
EBITDA
$-19,118,000
Free Cash Flow
$-9,874,000
Enterprise Value
$65,351,904
Total Cash
$9,671,000
Total Debt
$22,344,000
Shares Out
14,400,175
Trailing EPS
$-2.30
Book Value
$-1.62
ROE
—
ROA
-56.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 200,000 | -21,816,000 | -26,173,000 | 18,131,000 | 35,723,000 | -17,592,000 | -18,546,000 |
| Dec 2024 | 342,000 | -31,975,000 | -39,400,000 | 27,337,000 | 36,194,000 | -8,857,000 | -21,326,000 |
| Dec 2023 | 654,000 | -38,260,000 | -49,504,000 | 52,341,000 | 38,951,000 | 13,390,000 | -30,171,000 |
| Dec 2022 | 473,000 | -44,557,000 | -29,918,000 | 44,493,000 | 41,256,000 | 3,237,000 | -39,011,000 |
TTM Snapshot
Revenues TTM
$197,000
NetIncome TTM
$-39,518,000
OpCashFlow TTM
—
Assets (Latest)
$23,041,000
Forward EPS
$-2.44
Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $3.42 · call volume: 100 · put volume: 0Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SMNR | Semnur Pharmaceuticals, Inc. | $46.04M | $0.20 | — |
| RFL | Rafael Holdings, Inc. | $46.95M | $0.91 | — |
| NMAD | NOMAD POWER SOLUTIONS, INC. | $48.30M | $3.00 | — |
| MREO | Mereo BioPharma Group plc | $43.84M | $0.27 | — |
| APLM | Apollomics Inc. | $49.09M | $16.84 | — |
News headlines (Yahoo Finance, 1h cache)
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application
2026-11-12 17:09 · Yahoo
Clene Inc. (CLNN) Tops Q3 Earnings Estimates
2026-11-04 14:05 · Yahoo
Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights
2026-11-04 13:30 · Yahoo
Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision
2026-10-02 12:02 · Yahoo
Clene to Present at Upcoming Investor Conferences
2026-09-22 12:00 · Yahoo
Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
2026-09-21 12:30 · Yahoo
Clene Announces $4 Million Registered Direct Offering
2026-09-15 13:00 · Yahoo
Clene to Present at Upcoming September Investor Conferences
2026-09-03 12:00 · Yahoo
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses
2026-08-19 22:03 · Yahoo
Clene to Present at the Emerging Growth Conference
2026-08-17 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.